Trials / Recruiting
RecruitingNCT07214727
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer's Disease
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALN-5288 | ALN-5288 will be administered IT. |
| DRUG | Placebo | Placebo will be administered IT. |
Timeline
- Start date
- 2025-10-15
- Primary completion
- 2030-03-06
- Completion
- 2030-03-06
- First posted
- 2025-10-09
- Last updated
- 2026-03-31
Locations
6 sites across 2 countries: Canada, United Kingdom
Source: ClinicalTrials.gov record NCT07214727. Inclusion in this directory is not an endorsement.